50-year Wall Street legend: “Sell this tech stock NOW”

Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.

You can watch for it for free, right here.

John Tilton Biography and Net Worth

Insider of Biohaven

Mr. Tilton has over 20 years of experience commercializing drug products and leading global pharmaceutical business units. He joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton played a central role in the successful global launches of Soliris, as well as building operational infrastructure, for 4 orphan indication launches in over 30 countries for Alexion. Previously, Mr. Tilton held leadership roles of increasing responsibility at Pfizer, Agouron and Sanofi with therapeutic focus in the orphan, oncology and specialty markets. Mr. Tilton holds a Bachelor of Science degree in Business Administration from the University of South Carolina — Darla Moore School of Business.

What is John Tilton's net worth?: The estimated net worth of John Tilton is at least $2.41 million as of June 10th, 2020. Mr. Tilton owns 52,770 shares of Biohaven stock worth more than $2,405,784 as of November 23rd. This net worth approximation does not reflect any other investments that Mr. Tilton may own. Learn More about John Tilton's net worth.
How old is John Tilton?: Mr. Tilton is currently 56 years old. There are 5 older executives and no younger executives at Biohaven. The oldest executive at Biohaven is Mr. Matthew Buten, Chief Financial Officer, who is 63 years old. Learn More on John Tilton's age.
How do I contact John Tilton?: The corporate mailing address for Mr. Tilton and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on John Tilton's contact information.
Has John Tilton been buying or selling shares of Biohaven?: John Tilton has not been actively trading shares of Biohaven over the course of the past ninety days. Most recently, John Tilton sold 52,000 shares of the business's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $67.38, for a transaction totalling $3,503,760.00. Following the completion of the sale, the insider now directly owns 52,770 shares of the company's stock, valued at $3,555,642.60. Learn More on John Tilton's trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

John Tilton Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/10/2020	Sell	52,000	$67.38	$3,503,760.00	52,770
3/12/2019	Sell	10,000	$50.11	$501,100.00	10,000
1/10/2019	Sell	10,500	$37.67	$395,535.00	10,500
11/1/2017	Sell	30,000	$29.25	$877,500.00	30,000

John Tilton Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $45.59

$45.08

$47.15

50 Day Range

MA: $48.95

$38.08

$53.73

2 Week Range

Now: $45.59

$26.80

$62.21

Volume

691,029 shs

Average Volume

1,129,495 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

50-year Wall Street legend: “Sell this tech stock NOW”

From Chaikin Analytics | Ad